[Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine].
A patient suffering Cushing disease is presented in whom the administration of ciproheptadine, bromocriptine and sodium valproate in a single dose did not manage to control the clinical-biologic manifestations of the process. Combined treatment with 1.200 mg/day of sodium valproate and 15 mg/day of bromocriptine induced a complete clinical-biological remission, being arterial pressure the last parameter to normalize. The patient who has always refused to undergo surgery has stayed with this treatment for three years, maintaining remission and without appearance of side effects. On two occasions (after one and a half years and after two and half years) the transitory interruption of treatment induced in a few weeks an increase in plasma cortisol levels which again normalized after treatment was re-established. There were no clinical-biological data, pharmacological tests which permitted the prediction of these therapeutic results and therefore, the therapeutic response obtained is not indicative of any specific etiological subtype of Cushing disease.
García Rojas
J F
JF
Departamento de Medicina Interna, Universidad de Cádiz.
Mangas Rojas
A
A
Barba Chacón
A
A
García Osle
M
M
Zamora Madaria
E
E
D001971:Bromocriptine / Q000627:therapeutic use*; D002908:Chronic Disease; D003480:Cushing Syndrome / Q000188:drug therapy*; D003533:Cyproheptadine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors; D014635:Valproic Acid / Q000627:therapeutic use*
D003533:Cyproheptadine; D001971:Bromocriptine; D014635:Valproic Acid
Remisión clínica de una enfermedad de Cushing mediante tratamiento combinado con valproato sódico y bromocriptina.